University at Buffalo - The State University of New York
Skip to Content
UBMD Physicians' Group

Clinical Trials

Vascular Benefits of Adding Carvedilol CR to Type 2 Diabetic Patients on ACEi: Effects on Oxidative Stress and Inflammation.

Lisniopril is a blood-pressure lowering drug that belongs to a class of medications called Angiotensin-Converting Enzyme inhibitors or ACEi. Carvedilol belongs to a class of blood pressure lowering medications called beta-blockers that are used for the treatment of high blood pressure, especially in patients with coronary heart disease. Diabetics are known to be at increased risk of coronary artery disease (disease affecting the vessels supplying blood to the heart). Controlled-release carvedilol (Carvedilol CR) is approved by the FDA. In this study, clinical trial formulation of controlled-release carvedilol will be used.

The purpose of this study is to determine if the addition of carvedilol to diabetic patients with high blood pressure who are already receiving the blood pressure medication

Eligibility

You are being asked to participate in this study because you have been diagnosed with type 2 diabetes mellitus for at least four months, have high blood pressure and have been on treatment with the cholesterol-lowering drugs called statins for at least four months.

Reimbursement

$400

Investigator

Paresh Dandona, MD

Contact Information

Name: Teekam Lohano
Phone: 716-887-5104
Email: tlohano@kaleidahealth.org